View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 2, 2020

Gilead initiates two studies of remdesivir in UK

Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.

The two studies will be conducted at 15 sites in the country, primarily in England and Scotland.

One of the trials will involve patients with moderate symptoms and the other will enrol patients in a serious condition.

Read the full article here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU